多发性骨髓瘤T细胞衔接抗体治疗前后免疫靶点基因的单打击与双打击事件
该研究报道一例经BCMA靶向双特异性抗体治疗的重度预处理多发性骨髓瘤患者出现纯合BCMA基因缺失,BCMA蛋白表达丢失持续至后续复发且对抗BCMA抗体药物偶联物无反应。对100例多发性骨髓瘤患者(50例新诊断、50例复发/难治)行全基因组和RNA测序,发现免疫治疗靶点基因异常比例显著,GPRC5D杂合缺失占15%居首。
要点
- BCMA靶向双特异性抗体治疗后可见纯合BCMA基因缺失及持续BCMA蛋白表达丢失。
- 免疫治疗靶点基因杂合缺失未降低相应基因表达,但可能为纯合缺失和抗原丢失复发奠定基础。
- 靶点基因异常以GPRC5D杂合缺失15%最常见,其次CD38 10%、SDC1 5%、TNFRSF17 4%。
核心结论
- 多发性骨髓瘤患者在T细胞衔接免疫治疗前即存在免疫靶点基因的预存脆弱性,治疗后可见纯合缺失。
研究设计与样本
- 研究报道一例重度预处理多发性骨髓瘤患者接受BCMA靶向T细胞重定向双特异性抗体治疗后出现纯合BCMA基因缺失。
- 对100例多发性骨髓瘤患者(50例新诊断、50例复发/难治)进行全基因组测序和RNA测序。
主要发现
- 一例重度预处理多发性骨髓瘤患者经BCMA靶向双特异性抗体治疗后出现纯合BCMA(TNFRSF17)基因缺失。
- BCMA蛋白表达丢失持续至后续复发,且对抗BCMA抗体药物偶联物治疗无反应。
- 100例多发性骨髓瘤患者中免疫治疗靶点基因异常比例显著,GPRC5D杂合缺失占15%居首。
- CD38杂合缺失占10%,SDC1杂合缺失占5%,TNFRSF17杂合缺失占4%。
- 上述杂合缺失未降低相应基因表达水平,但可能作为第一次打击驱动纯合缺失获得及靶向免疫治疗后抗原丢失复发。
临床怎么用
- 接受T细胞衔接免疫治疗的多发性骨髓瘤患者应关注靶点抗原丢失导致的复发及对同类靶向药物无反应。
- 免疫治疗靶点基因杂合缺失状态可能提示后续纯合缺失和抗原丢失复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T cell-engaging immunotherapies exert unprecedented single-agent activity in multiple myeloma (MM), thereby putting a yet unexplored selective pressure on the clonal architecture. In this study, we report on homozygous BCMA (TNFRSF17) gene deletion after BCMA-targeting T cell-redirecting bispecific antibody therapy in a heavily pretreated MM patient. Loss of BCMA protein expression persisted over subsequent relapses, with no response to treatment with anti-BCMA antibody drug conjugate. In light of the multiple alternative targets that are emerging in addition to BCMA, we extended our analyses to delineate a more complete picture of genetic alterations that may have an impact on immunotherapy targets in MM. We performed whole-genome sequencing and RNA sequencing in 100 MM patients (50 were newly diagnosed; 50 were relapsed/refractory) and identified a significant proportion of patients with aberrations in genes encoding immunotherapy targets; GPRC5D ranked first with 15% heterozygous deletions, followed by CD38 (10%), SDC1 (5%), and TNFRSF17 (4%). Notably, these heterozygous deletions did not lower the expression levels of respective genes, but they may represent a first hit that drives the acquisition of homozygous deletions and subsequent antigen-loss relapse upon targeted immunotherapy. In summary, we show preexisting vulnerability in genes encoding immunotargets before and homozygous deletions after T cell-engaging immunotherapy.
引用
- Truger MS, Duell J, Zhou X, et al. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Adv. 2021. PMID: 34471932. doi:10.1182/bloodadvances.2021004418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。